Il bambino con il batticuore in Pronto Soccorso: dalla teoria alla pratica andata e ritorno

Palpitations are a common cause of complaint in the paediatric population and can be a reason of serious concern for children, adolescents and parents. Despite this, palpitations are known to have a benign prognosis, but still are cause of referral to the Emergency Unit (EU). The aim of the present retrospective study was to make a review of prevalence and long-term prognosis of emergency accesses for palpitations between 2009-2015. The study was conducted in the EU of the Paediatric Hospital \u201cBurlo Garofolo\u201d, Trieste, Italy. Despite a low prevalence of access to the EU, namely 0.1%, 96 patients in a time span of 7 years, 16.7% of patients (n = 16) had an underlying arrhythmic cause for the symptom. The presence of a heart rate above 150 beats per minute was highly suggestive of cardiac arrhythmia, more often of paroxysmal supraventricular tachycardia. As far as the long-term follow-up is concerned, 10.4% of patients (n = 10) received medical therapy and 6.2% (n = 6) underwent transcatheter ablation for supraventricular arrhythmia. In conclusion, palpitations turned out to be an infrequent cause of access to the EU. Nonetheless, 1 out of 6 patients requires long term medical therapy or percutaneous intervention

Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy

Incidence of neuroepithelial Primary Brain Tumors (nPBT) varies, ranging from 7.3 to 11.6 cases/100,000/year across Europe. We present incidence and survival of nPBT in the Emilia-Romagna region (ER), Italy. This study is the largest in Southern Europe. Specialists in neurosurgery, neurology, neuroradiology, oncology, radiotherapy, genetics, and pathology of ER notified all suspected nPBT adult cases residing in ER (4,337,966 inhabitants) observed during 2009. Furthermore, through ICD-9 discharge codes, we identified and reviewed all possible cases. Neuroepithelial PBT diagnosis was based on histological or radiological findings. We included 400 incident nPBT cases, of which 102 (25%) were retrospectively identified. These latter were significantly older. The standardized incidence was 10.5/100,000/year (95% CI 9.4\u201311.5), higher for men. It was 9.2/100,000/year (95% CI 8.3\u201310.2) for astrocytic tumors, 0.6/100,000/year (95% CI 0.4\u20130.9) for oligodendroglial tumors, and 7.1 (95% CI 6.3\u20138.0) for glioblastoma (GBM). Among GBM patients, median survival was 249\ua0days if prospectively identified vs. 132\ua0days when identified through ICD-9 codes (p\ua0<\ua00.0001). The incidence of nPBT in the ER region is among the highest in the literature. Older patients were more likely to escape an active surveillance system. This should be considered when comparing incidence rates across studies, giving the increasing number of elderly people in the general population

Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)

The members of the PERNO Study Group were not individually captured in the metadata of the original publication. They are included in the metadata of this publication

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70\ua0years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70\ua0years; PS 0\u20133; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1\ua0months (95\ua0% CI 8.8\u201313.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6\ua0months (95\ua0% CI 8.6\u201314.6), and 9.3\ua0months (95\ua0% CI 8.1\u201310.6) in patients treated with RT alone (P\ua0=\ua00.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2\ua0months, 95\ua0% CI 11.5\u201322.9) (P\ua0=\ua00.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only

Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging

Erratum to: J Neurooncol (2015) 123:93\u2013102 DOI 10.1007/s11060-015-1766-5 Three participants were missing in the Appendix (listing the members of the PERNO study group) in the original publication. They are included in the complete list in the Appendix below